ClinicalTrials.gg
Active, not recruitingNCT04191304NATRONUpdated Jul 10, 2026Results posted

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

A Phase 3 interventional study of Benralizumab and Placebo in Hypereosinophilic Syndrome, sponsored by AstraZeneca. Active, not recruiting at 52 sites in 17 countries. Open to participants aged 12 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
12 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Hypereosinophilic Syndrome with a site in United States — 3 open to participants now, 8 under way, 3 of them phase 3. Hypereosinophilic Syndrome · United States.

Enrollment
3rd of 21
134 · median 68
Started
2020
the only one that year
Phase 3
8 of 23
1 open now
Registered
18th of 23
by date
Lead sponsor
3 of 23
AstraZeneca

Among the 23 studies in Hypereosinophilic Syndrome with a site in United States, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 3, and was the 18th registered.

Hypereosinophilic Syndrome

40 studies on the registry are indexed under Hypereosinophilic Syndrome; 8 are open to participants now.

Browse Hypereosinophilic Syndrome studies →

Open to participants now

3 of the 23 studies in Hypereosinophilic Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Hypereosinophilic Syndrome studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 12 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hypereosinophilic Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic syndrome (HES). This study comprises 2 distinct periods (together defined as the 'main study'): A 24-week, DB treatment period, during which patients will be randomised to receive either benralizumab or placebo, in addition to their prior stable HES background therapy, and an open-label extension (OLE) period, during which all patients will receive benralizumab.

The primary database lock (DBL) will occur when approximately 38 patients have had their first HES worsening/flare event during the DB treatment period and all randomised patients have had the opportunity to be followed up for the 24-week DB treatment period.

A patient must complete the 24-week DB treatment period on investigational product (IP) to be eligible to enter the OLE treatment period. The final DBL will occur after the last patient completes the OLE.

Read the detailed description

This is a multicentre, randomised, DB, parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab 30 mg versus placebo administered by SC injection Q4W in patients with HES. This study will be conducted at approximately 68 sites in 18 countries.

The target patient population is male and female patients 12 years of age and older with symptomatic active HES. Eligible patients must be negative for the FIP1L1-PDGFRA fusion tyrosine kinase gene translocation.

Potentially eligible patients will enter a 3-day screening period and will be required to have documented stable HES therapy for at least 4 weeks prior to Visit 1 and AEC ≥ 1000 cells/μL at local laboratory testing to proceed to the second day of the screening period. Patients will be assessed for corticosteroid responsiveness (defined as an AEC \< 1000 cells/μL after 2 days of OCS [prednisone/prednisolone] 1 mg/kg/day given on top of the patient's background therapy for HES) prior to randomisation; other OCSs in equivalent doses are permitted. Patients who are not corticosteroid responsive or fail any other eligibility criteria will be screen failed.

It is expected that approximately 120 patients will be randomised at a 1:1 ratio at the randomisation/baseline visit (Visit 3) to receive either benralizumab or matching placeboQ4W for a 24-week DB treatment period. Recruitment may continue beyond 120 patients if required to achieve the target number of HES worsening/flares. Recruitment of adolescent patients is targeted to be broadly in line with expected prevalence rates of adolescents in the overall population. Approximately 4 to 6 adolescent patients (aged 12 to 17) are targeted to be randomised. Randomisation will be stratified. Approximately 40 patients will participate in a noninterventional interview to collect data on HRQoL and the patients' experience during the DB portion of the study.

All patients will remain on stable dose(s) and regimen of background HES therapy during the screening period and throughout 36 weeks of treatment (until Visit 12/Week 36 when the therapy can be adjusted). During this time, background HES therapy may only be modified if a patient has an HES clinical worsening/flare or an AE thought to be due to background therapy.

AstraZeneca, sites, and patients will be blinded to the absolute eosinophil, basophil, and monocyte counts, differential blood counts (percentages) for all WBCs (eosinophils, basophils, monocytes, neutrophils, and lymphocytes), and biopsy cell counts (if applicable) after randomisation/baseline (Visit 3/Week 0), during the entire DB treatment period, and for the first 4 weeks of the OLE treatment period (until Visit 10/Week 28) after which no blinding to WBC counts or biopsy cell counts is required. After the primary DBL, AstraZeneca will become unblinded to all patients' blood and biopsy cell counts obtained during DB treatment period.

The final dose of the DB treatment period will be given at Week 20, and the DB treatment period will complete at Week 24.

All patients who complete the DB treatment period on IP may be eligible to continue into an OLE treatment period on benralizumab (30 mg SC Q4W). The OLE is intended to allow treatment with open-label benralizumab for at least 1 year for adults and at least 2 years for adolescents after completion of the DB treatment period of the study (earlier enrolled patients may therefore be in the OLE for longer than 1 year). AstraZeneca may choose to extend the study depending on the overall development program. Moreover, AstraZeneca reserves the right of terminating the OLE early (eg, if development of the asset is terminated or marketing authorisation is obtained).

The primary DBL will occur when approximately 38 patients have had their first HES worsening/flare event during the DB treatment period and all randomised patients have had the opportunity to be followed up for the 24-week DB treatment period. Treatment allocation will remain blinded until the primary DBL. A patient must complete the 24-week DB treatment period on IP to be eligible to enter the OLE treatment period. The final DBL will occur after the last patient completes the OLE. Data from the OLE treatment period of the study will be presented in an addendum to the primary analysis CSR and/or a separate OLE treatment period CSR.

03

Conditions studied

  • Hypereosinophilic Syndrome

Keywords

  • benralizumab
  • Hypereosinophilic Syndrome (HES)
04

Who can participate

Ages eligible
12 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of the signed and dated written of the patient or the patient's legally authorised representative, and informed assent from the patient (per local regulations) prior to any mandatory study-specific procedures, sampling, and analyses
  2. Males and females 12 years of age and older at the time of signing the ICF
  3. Documented diagnosis of HES (history of persistent eosinophilia > 1500 cells/μL without secondary cause on 2 examinations [interval ≥ 1 month; Valent et al 2012] and evidence of end organ manifestations attributable to the eosinophilia)
  4. Documented negative testing for the FIP1L1-PDGFRA fusion tyrosine kinase gene translocation
  5. Stable HES treatment dose(s) and regimen for ≥ 4 weeks at the time of Visit 1
  6. Signs or symptoms of HES worsening/flare and/or laboratory abnormalities indicative of HES worsening/flare (other than isolated eosinophilia) at Visit 1 OR a documented history of 2 or more HES worsening/flares within 12 months prior to Visit 1 requiring an escalation in therapy

    a. At least one flare within the past 12 months must not be related to a decrease in HES therapy during the 4 weeks prior to the flare

  7. AEC ≥ 1000 cells/μL at Visit 1 (assessed by local laboratory)
  8. responsiveness defined as an AEC \< 1000 cells/μL after a 2-day course of OCS (prednisone/prednisolone) 1 mg/kg/day at Visit 2 (assessed by local laboratory). Other OCSs in equivalent doses are permitted
  9. must agree to use a highly effective method of (confirmed by the investigator) from enrolment, throughout the study duration, and within 12 weeks after last dose of IP and have a negative urine dipstick pregnancy test result on Visit 1. Highly effective methods of birth control (those that can achieve a failure rate of less than 1% per year when used consistently and correctly) include:

    1. Combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal
    2. Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable
    3. Intrauterine device
    4. Intrauterine hormone-releasing system
    5. Bilateral tubal occlusion
    6. Sexual abstinence, ie, refraining from heterosexual intercourse (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient)
    7. Vasectomised sexual partner (provided that partner is the sole sexual partner of the WOCBP study patient and that the vasectomised partner has received medical assessment of the surgical success)

Exclusion criteria

Exclusion Criteria

  1. Life-threatening HES and/or HES complication(s) as judged by the investigator:

    1. Medical intervention for HES-related life-threatening event(s) within 12 weeks prior to randomization
    2. History of thrombotic complications, stroke, or significant cardiac damage related to HES, if the respective events were life threatening and currently represent a risk of life-threatening disease complications. Events that occurred in the past but considered resolved or stable, can be accepted if, as per investigator's judgment, participation in the study will not put the patient at risk
    3. Disease severity that in the opinion of the investigator makes the patient inappropriate for inclusion in the study
  2. Presence of FIP1L1-PDGFRA fusion tyrosine kinase gene translocation or other known imatinib-sensitive mutation
  3. Definitive diagnosis of eosinophilic granulomatosis with polyangiitis
  4. Known, preexisting, endocrine, , metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities that are not associated with HES and are uncontrolled with standard treatment which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete the entire duration of the study
  5. Hypereosinophilia of unknown significance
  6. Cardiovascular: Documented history of any clinically significant cardiac damage, clinically significant echocardiography (if available) or findings within 12 months prior to Visit 1 or clinically significant ECG findings at screening that in the opinion of the investigator may put the patients at risk
  7. Known currently active liver disease

    1. Chronic stable and C (including positive testing for hepatitis B surface antigen or antibody) or other stable chronic liver disease are acceptable if patient otherwise meets eligibility criteria. Stable chronic liver disease should generally be defined by the absence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal or gastric varices, or persistent jaundice, or cirrhosis
    2. or AST level ≥ 3 × during the screening period (AST or ALT > 5 × ULN if documented HES with liver manifestations). Transient increase of AST/ALT level that resolves by the time of randomisation is acceptable if, in the investigator's opinion, the patient does not have an active liver disease and meets other eligibility criteria
  8. Current or history of within 5 years before the screening visit with the following exceptions:

    1. Patients treated for in situ carcinoma of the cervix who have completed curative therapy and are in remission for at least 12 months prior to signing the and
    2. Patients with basal cell or superficial squamous skin cancer
    3. Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained
  9. Diagnosis of systemic mastocytosis
  10. Chronic or ongoing active infections requiring systemic treatment, as well as clinically significant viral, bacterial, or fungal infection within 4 weeks prior to Visit 1
  11. A helminth parasitic infection diagnosed within 24 weeks prior to Visit 1 that has not been treated or has failed to respond to standard of care therapy. A confirmation of a complete resolution of any helminth parasitic infection prior to Visit 1 should be available
  12. A history of known immunodeficiency disorder other than that explained by the use of OCS or other therapy taken for HES. Positive test

14. Evidence of prior benralizumab treatment failure

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Benralizumab arm

    1x Benralizumab SC injection

    Biological: Benralizumab

  • Placebo comparator
    Placebo arm

    1x Benralizumab matching placebo SC injection

    Biological: Placebo

Interventions

  • BiologicalBenralizumab

    Benralizumab solution for injection in an accessorised prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks

  • BiologicalPlacebo

    Matching placebo solution for injection in an APFS will be administered SC every 4 weeks

06

What researchers measure

Primary outcomes

  1. Time to First HES Worsening/Flare During the DB Treatment Period

    The time to first HES worsening/flare is calculated as: start date of the first HES worsening - date of randomisation + 1. For participants who do not experience a HES worsening/flare, the time to first HES worsening/flare is right censored at the end of the DB period corresponding to the earliest date (date of the first of Benra open label dose, study day 183, date of last contact, and data cut-off date). The number of participants with events and censored observations is presented.

    Time frame: DB period (Baseline to Week 24)

Secondary outcomes

  1. Proportion of Patients Who Experience an HES Worsening/Flare During the DB Treatment Period

    The proportion of participants who experience an HES worsening/flare or who withdraw from the study prior to completing the 24-week DB treatment period. The proportion is calculated as the number of participants with an HES worsening/flare or withdrawal divided by the total number of participants in the analysis population. The number and proportion (expressed as percentage) or participants who experienced HES worsening/flare is presented.

    Time frame: DB period (Baseline to Week 24)

  2. Number of HES Worsenings/Flares (Annualised Rate) During the DB Period

    The annualised rate of HES worsening/flare events was analysed using a negative binomial regression model adjusted for region, with the logarithm of follow-up time included as an offset variable. Annualized flare rates are model estimated marginal rates. A separate HES worsening/flare is considered if the start date of an HES worsening/flare is at least 14 days apart from the stop date of a preceding HES worsening/flare.

    Time frame: DB period (Baseline to Week 24)

  3. Time to First Haematologic Relapse (AEC ≥ 1000 Cells/μL) During the DB Period

    Time to first haematologic relapse is calculated as start date of the first haematologic relapse - date of randomisation + 1. Haematologic relapse is defined as the first occurrence of an absolute eosinophil count (AEC) ≥ 1000 cells/μL post-baseline. For participants who do not experience haematologic relapse, the time to first haematologic relapse is right censored at the end of the DB period corresponding to the earliest date of (date of the first of Benra open label dose, study day 183, date of last contact, and data cut-off date). The number of participants with events and censored observations is presented.

    Time frame: DB period (Baseline to Week 24)

  4. Fatigue Severity (PROMIS Fatigue Short Form 7a) at Week 24

    Fatigue severity was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a questionnaire. Each item is scored on a 5-point Likert scale (1 to 5), and the total raw score is converted to a T-score. T-scores are standardized such that 50 represents the population mean with a standard deviation of 10. Standardized T-score range is from 29.4 to 83.2, with higher scores indicating more severe fatigue. A reduction in T-score indicates an improvement in fatigue severity. The least squares (LS) mean (95% CI) change from baseline in T-score at Week 24 is presented.

    Time frame: Week 24

  5. Proportion of Patients Who Have Haematologic Relapse During the DB Treatment Period

    The proportion of patients who have a haematologic relapse or withdraw from the study over the DB treatment period is defined as the number of participants who have a first haematologic relapse or withdraw prior to completing in the DB period divided by the number of participants in the the analysis. Haematologic relapse is defined when AEC post baseline is ≥ 1,000 cells/Ul for the first time. The number and proportion (expressed as percentage) of participants who experienced haematologic relapse is presented.

    Time frame: DB period (Baseline to Week 24)

  6. Proportion of Patients Who Have AEC < 500 Cells/μL for 24 Weeks

    The proportion of participants who maintained an AEC of \< 500 cells/µL throughout the 24-week DB treatment period. The proportion is defined as the number of participants who maintained AEC \< 500 cells/µL divided by the total number of participants in the analysis population. The number and proportion (expressed as percentage) of participants who maintained AEC \< 500 cells/µL is presented.

    Time frame: DB period (Baseline to Week 24)

  7. Proportion of Patients Who Require an Increase in Corticosteroid Dose From Baseline at Any Point in the DB Treatment Period

    The proportion of patients who required an increase in systemic corticosteroids (SCS) from baseline during the 24-week DB treatment period. An increase in SCS includes an increase of at least 1 mg prednisone equivalent for participants receiving oral corticosteroids at baseline, or initiation of a new or additional course of systemic corticosteroids for treatment of HES or a closely related condition. Baseline is defined as the last valid value on or prior to randomisation. The number and proportion (expressed as percentage) of participants who require an increase in SCS from baseline.

    Time frame: DB period (Baseline to Week 24)

  8. Health-Related Quality of Life (HRQoL) (Short Form-36 Version 2 [SF-36v2])

    HRQoL was assessed using the 36 Item Short Form Health Survey, version 2 (SF 36v2). Change from baseline in HRQoL was evaluated using the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores at Week 12 and Week 24 during the DB treatment period. PCS and MCS scores are norm-based and standardized to a general population with a mean of 50 and a standard deviation of 10, with higher scores indicating better HRQoL. Scores generally range from 0 to 100. PCS and MCS scores are derived from weighted combinations of domain scores using standard scoring algorithms. An increase in score indicates an improvement. LS mean (95% CI) changes from baseline for PCS and MCS scores are presented.

    Time frame: DB period (Baseline to Week 24)

  9. Patient Global Impression of Severity (PGI-S)

    Patient Global Impression of Severity (PGI-S) is a single-item, participant-reported assessment of disease severity during the DB treatment period. PGI-S captures the participant's perception of overall symptom severity at the time of assessment using categorical response options ranging from "No symptoms" to "Very severe". The number and percentage of participants in each response category are presented at each timepoint.

    Time frame: DB period (Baseline to Week 24)

  10. Patient Global Impression of Change (PGI-C)

    Patient Global Impression of Change (PGI-C) is a single-item, participant-reported assessment that captures the participant's overall evaluation of response to treatment during the DB treatment period. PGI-C reflects the participant's perception of change in disease status compared with baseline using categorical response options ranging from "Much better" to "Much worse." The number and percentage of participants in each response category are presented at each time point.

    Time frame: DB period (Baseline to Week 24)

  11. Serum Benralizumab Concentrations

    Serum concentrations of benralizumab measured over time during the DB period to characterise the pharmacokinetics of benralizumab in participants with HES. Baseline is defined as the last valid value on or prior to the date of randomisation.

    Time frame: DB period (Baseline to Week 24)

  12. Anti-Benralizumab Antibodies and Neutralizing Antibodies (nAbs)

    Immunogenicity of benralizumab, as assessed by the incidence and prevalence of anti-drug antibodies (ADA), including nAbs, measured from baseline through the 24-week DB treatment period in participants with HES.

    Time frame: DB period (Baseline to Week 24)

07

Results

Posted Jul 10, 2026

Participant flow

A total of 134 participants were randomized at 40 study centres across 15 countries. Of the 134 participants randomized, 133 received treatment during the 24-week double-blind (DB) period. One participant did not receive treatment due to withdrawal.

Double-blind (DB) Treatment Period
Participant flow — Double-blind (DB) Treatment Period
MilestoneBenraPlacebo
Started6766
Completed6562
Not completed24
Withdrew: Death10
Withdrew: Withdrawn from study due to severe non-compliance to protocol10
Withdrew: Withdrawal by subject04
Open-label Extension (OLE) Period
Participant flow — Open-label Extension (OLE) Period
MilestoneBenraPlacebo
Started6561
Completed00
Not completed6561
Withdrew: Ongoing5650
Withdrew: Withdrawal by subject64
Withdrew: Lost to follow-up01
Withdrew: Adverse event11
Withdrew: Withdrawal for other reason25

Outcome measures

PrimaryTime to First HES Worsening/Flare During the DB Treatment Period

The time to first HES worsening/flare is calculated as: start date of the first HES worsening - date of randomisation + 1. For participants who do not experience a HES worsening/flare, the time to first HES worsening/flare is right censored at the end of the DB period corresponding to the earliest date (date of the first of Benra open label dose, study day 183, date of last contact, and data cut-off date). The number of participants with events and censored observations is presented.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Count of participants · Participants
Time to First HES Worsening/Flare During the DB Treatment Period
ParticipantsBenraPlacebo
Event1328
Censored5438
Statistical analysis
  • Benra vs Placebo · Stratified log rank test · p = 0.0024 · Hazard ratio (hr): 0.35 · 95% CI 0.18 to 0.69The analysis was performed using a Cox proportional hazards model including treatment group and region as covariates. An HR less than 1 would indicate a reduction in risk of flaring in Benra.
SecondaryProportion of Patients Who Experience an HES Worsening/Flare During the DB Treatment Period

The proportion of participants who experience an HES worsening/flare or who withdraw from the study prior to completing the 24-week DB treatment period. The proportion is calculated as the number of participants with an HES worsening/flare or withdrawal divided by the total number of participants in the analysis population. The number and proportion (expressed as percentage) or participants who experienced HES worsening/flare is presented.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Count of participants · Participants
Proportion of Patients Who Experience an HES Worsening/Flare During the DB Treatment Period
ParticipantsBenraPlacebo
Proportion of Patients Who Experience an HES Worsening/Flare During the DB Treatment Period1530
Statistical analysis
  • Benra vs Placebo · Cochran-Mantel-Haenszel · p = 0.003 · Risk ratio (rr): 0.48 · 95% CI 0.29 to 0.80
  • Benra vs Placebo · Cochran-Mantel-Haenszel · p = 0.003 · Pooled percentage difference: -24.07 · 95% CI -39.49 to -8.66The pooled percentage difference and 95% CI is based on Mantel-Haenszel weight adjusted by region.
  • Benra vs Placebo · Regression, Logistic · p = 0.004 · Odds ratio (or): 0.31 · 95% CI 0.14 to 0.69An odds ratio less than 1 would indicate lower odds of the event in Benra compared with placebo.
SecondaryNumber of HES Worsenings/Flares (Annualised Rate) During the DB Period

The annualised rate of HES worsening/flare events was analysed using a negative binomial regression model adjusted for region, with the logarithm of follow-up time included as an offset variable. Annualized flare rates are model estimated marginal rates. A separate HES worsening/flare is considered if the start date of an HES worsening/flare is at least 14 days apart from the stop date of a preceding HES worsening/flare.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Number · flares per year
Number of HES Worsenings/Flares (Annualised Rate) During the DB Period
flares per yearBenraPlacebo
Number of HES Worsenings/Flares (Annualised Rate) During the DB Period0.41 (0.24 to 0.71)1.23 (0.88 to 1.72)
Statistical analysis
  • Benra vs Placebo · Negative binomial model · p = <0.001 · Rate ratio: 0.34 · 95% CI 0.18 to 0.63Analysis used a negative binomial model adjusted by region. The logarithm of the follow-up time was used as an offset variable in the model.
SecondaryTime to First Haematologic Relapse (AEC ≥ 1000 Cells/μL) During the DB Period

Time to first haematologic relapse is calculated as start date of the first haematologic relapse - date of randomisation + 1. Haematologic relapse is defined as the first occurrence of an absolute eosinophil count (AEC) ≥ 1000 cells/μL post-baseline. For participants who do not experience haematologic relapse, the time to first haematologic relapse is right censored at the end of the DB period corresponding to the earliest date of (date of the first of Benra open label dose, study day 183, date of last contact, and data cut-off date). The number of participants with events and censored observations is presented.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Count of participants · Participants
Time to First Haematologic Relapse (AEC ≥ 1000 Cells/μL) During the DB Period
ParticipantsBenraPlacebo
Event539
Censored6227
Statistical analysis
  • Benra vs Placebo · Stratified log rank test · p = <0.0001 · Hazard ratio (hr): 0.08 · 95% CI 0.03 to 0.20The analysis was performed using a Cox proportional hazards model including treatment group and region as covariates. An HR less than 1 would indicate a reduction in risk of relapse for participants in Benra.
SecondaryFatigue Severity (PROMIS Fatigue Short Form 7a) at Week 24

Fatigue severity was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a questionnaire. Each item is scored on a 5-point Likert scale (1 to 5), and the total raw score is converted to a T-score. T-scores are standardized such that 50 represents the population mean with a standard deviation of 10. Standardized T-score range is from 29.4 to 83.2, with higher scores indicating more severe fatigue. A reduction in T-score indicates an improvement in fatigue severity. The least squares (LS) mean (95% CI) change from baseline in T-score at Week 24 is presented.

Time frame:
Week 24
Reported as:
Least squares mean · T-score
Fatigue Severity (PROMIS Fatigue Short Form 7a) at Week 24
T-scoreBenraPlacebo
Fatigue Severity (PROMIS Fatigue Short Form 7a) at Week 24-8.6 (-10.6 to -6.6)-3.9 (-6.0 to -1.8)
Statistical analysis
  • Benra vs Placebo · Repeated measures ANCOVA analysis · p = 0.0017 · Mean difference (final values): -4.72 · 95% CI -7.6 to -1.8
SecondaryProportion of Patients Who Have Haematologic Relapse During the DB Treatment Period

The proportion of patients who have a haematologic relapse or withdraw from the study over the DB treatment period is defined as the number of participants who have a first haematologic relapse or withdraw prior to completing in the DB period divided by the number of participants in the the analysis. Haematologic relapse is defined when AEC post baseline is ≥ 1,000 cells/Ul for the first time. The number and proportion (expressed as percentage) of participants who experienced haematologic relapse is presented.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Count of participants · Participants
Proportion of Patients Who Have Haematologic Relapse During the DB Treatment Period
ParticipantsBenraPlacebo
Proportion of Patients Who Have Haematologic Relapse During the DB Treatment Period642
Statistical analysis
  • Benra vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio (rr): 0.14 · 95% CI 0.07 to 0.31
  • Benra vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Pooled percentage difference: -54.82 · 95% CI -68.17 to -41.46The pooled percentage difference and 95% CI is based on Mantel-Haenszel weight adjusted by region.
  • Benra vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 0.05 · 95% CI 0.02 to 0.13An odds ratio less than 1 would indicate lower odds of the event in Benra compared with placebo.
SecondaryProportion of Patients Who Have AEC < 500 Cells/μL for 24 Weeks

The proportion of participants who maintained an AEC of \< 500 cells/µL throughout the 24-week DB treatment period. The proportion is defined as the number of participants who maintained AEC \< 500 cells/µL divided by the total number of participants in the analysis population. The number and proportion (expressed as percentage) of participants who maintained AEC \< 500 cells/µL is presented.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Count of participants · Participants
Proportion of Patients Who Have AEC < 500 Cells/μL for 24 Weeks
ParticipantsBenraPlacebo
Proportion of Patients Who Have AEC < 500 Cells/μL for 24 Weeks618
Statistical analysis
  • Benra vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio (rr): 7.61 · 95% CI 3.93 to 14.74
  • Benra vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Pooled percentage difference: 78.93 · 95% CI 68.54 to 89.31The pooled percentage difference and 95% CI is based on Mantel-Haenszel weight adjusted by region.
  • Benra vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 87.87 · 95% CI 26.09 to 295.97An odds ratio greater than 1 would indicate higher odds of the event in Benra compared with placebo.
SecondaryProportion of Patients Who Require an Increase in Corticosteroid Dose From Baseline at Any Point in the DB Treatment Period

The proportion of patients who required an increase in systemic corticosteroids (SCS) from baseline during the 24-week DB treatment period. An increase in SCS includes an increase of at least 1 mg prednisone equivalent for participants receiving oral corticosteroids at baseline, or initiation of a new or additional course of systemic corticosteroids for treatment of HES or a closely related condition. Baseline is defined as the last valid value on or prior to randomisation. The number and proportion (expressed as percentage) of participants who require an increase in SCS from baseline.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Count of participants · Participants
Proportion of Patients Who Require an Increase in Corticosteroid Dose From Baseline at Any Point in the DB Treatment Period
ParticipantsBenraPlacebo
Proportion of Patients Who Require an Increase in Corticosteroid Dose From Baseline at Any Point in the DB Treatment Period1732
Statistical analysis
  • Benra vs Placebo · Cochran-Mantel-Haenszel · p = 0.005 · Risk ratio (rr): 0.51 · 95% CI 0.32 to 0.83
  • Benra vs Placebo · Cochran-Mantel-Haenszel · p = 0.005 · Pooled percentage difference: -23.78 · 95% CI -39.59 to -7.97The pooled percentage difference and 95% CI is based on Mantel-Haenszel weight adjusted by region.
  • Benra vs Placebo · Regression, Logistic · p = 0.005 · Odds ratio (or): 0.35 · 95% CI 0.16 to 0.73An odds ratio less than 1 would indicate lower odds of the event in Benra compared with placebo.
SecondaryHealth-Related Quality of Life (HRQoL) (Short Form-36 Version 2 [SF-36v2])

HRQoL was assessed using the 36 Item Short Form Health Survey, version 2 (SF 36v2). Change from baseline in HRQoL was evaluated using the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores at Week 12 and Week 24 during the DB treatment period. PCS and MCS scores are norm-based and standardized to a general population with a mean of 50 and a standard deviation of 10, with higher scores indicating better HRQoL. Scores generally range from 0 to 100. PCS and MCS scores are derived from weighted combinations of domain scores using standard scoring algorithms. An increase in score indicates an improvement. LS mean (95% CI) changes from baseline for PCS and MCS scores are presented.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Least squares mean · T-score
Health-Related Quality of Life (HRQoL) (Short Form-36 Version 2 [SF-36v2])
T-scoreBenraPlacebo
PCS (Week 12)5.2 (3.6 to 6.9)2.2 (0.5 to 3.8)
PCS (Week 24)6.7 (4.9 to 8.5)2.2 (0.3 to 4.0)
MCS (Week 12)5.4 (3.4 to 7.3)1.0 (-1.0 to 3.0)
MCS (Week 24)5.3 (3.2 to 7.3)2.7 (0.5 to 4.8)
Statistical analysis
  • Benra vs Placebo · Repeated measures ANCOVA analysis · p = 0.0104 · Mean difference (final values): 3.09 · 95% CI 0.7 to 5.4Estimate of the mean change from baseline at each visit in the benralizumab treatment group is compared to the placebo treatment group using a repeated measures ANCOVA analysis. The estimate presented corresponds to the SF-36v2 PCS score at Week 12.
  • Benra vs Placebo · Repeated measures ANCOVA analysis · p = 0.0008 · Mean difference (final values): 4.54 · 95% CI 1.9 to 7.1Estimate of the mean change from baseline at each visit in the benralizumab treatment group is compared to the placebo treatment group using a repeated measures ANCOVA analysis. The estimate presented corresponds to the SF-36v2 PCS score at Week 24.
  • Benra vs Placebo · Repeated measures ANCOVA analysis · p = 0.0026 · Mean difference (final values): 4.38 · 95% CI 1.6 to 7.2Estimate of the mean change from baseline at each visit in the benralizumab treatment group is compared to the placebo treatment group using a repeated measures ANCOVA analysis. The estimate presented corresponds to the SF-36v2 MCS score at Week 12.
  • Benra vs Placebo · Repeated measures ANCOVA analysis · p = 0.0852 · Mean difference (final values): 2.60 · 95% CI -0.4 to 5.6Estimate of the mean change from baseline at each visit in the benralizumab treatment group is compared to the placebo treatment group using a repeated measures ANCOVA analysis. The estimate presented corresponds to the SF-36v2 MCS score at Week 24.
SecondaryPatient Global Impression of Severity (PGI-S)

Patient Global Impression of Severity (PGI-S) is a single-item, participant-reported assessment of disease severity during the DB treatment period. PGI-S captures the participant's perception of overall symptom severity at the time of assessment using categorical response options ranging from "No symptoms" to "Very severe". The number and percentage of participants in each response category are presented at each timepoint.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Count of participants · Participants
Patient Global Impression of Severity (PGI-S)
ParticipantsBenraPlacebo
Baseline — No symptoms44
Baseline — Very mild108
Baseline — Mild1011
Baseline — Moderate3019
Baseline — Severe1021
Baseline — Very severe32
Week 4 — No symptoms137
Week 4 — Very mild1210
Week 4 — Mild2217
Week 4 — Moderate1622
Week 4 — Severe36
Week 4 — Very severe02
Week 8 — No symptoms158
Week 8 — Very mild1914
Week 8 — Mild1411
Week 8 — Moderate1222
Week 8 — Severe37
Week 8 — Very severe10
Week 12 — No symptoms229
Week 12 — Very mild1813
Week 12 — Mild1517
Week 12 — Moderate717
Week 12 — Severe44
Week 12 — Very severe01
Week 16 — No symptoms179
Week 16 — Very mild1415
Week 16 — Mild2014
Week 16 — Moderate816
Week 16 — Severe44
Week 16 — Very severe03
Week 20 — No symptoms167
Week 20 — Very mild1717
Week 20 — Mild1517
Week 20 — Moderate1115
Week 20 — Severe54
Week 20 — Very severe01
Week 24 — No symptoms1711
Week 24 — Very mild1716
Week 24 — Mild1314
Week 24 — Moderate1312
Week 24 — Severe46
Week 24 — Very severe00
SecondaryPatient Global Impression of Change (PGI-C)

Patient Global Impression of Change (PGI-C) is a single-item, participant-reported assessment that captures the participant's overall evaluation of response to treatment during the DB treatment period. PGI-C reflects the participant's perception of change in disease status compared with baseline using categorical response options ranging from "Much better" to "Much worse." The number and percentage of participants in each response category are presented at each time point.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGI-C)
ParticipantsBenraPlacebo
Week 4 — Much better178
Week 4 — Moderately better98
Week 4 — A little better1813
Week 4 — About the same1927
Week 4 — A little worse13
Week 4 — Moderately worse23
Week 4 — Much worse01
Week 8 — Much better207
Week 8 — Moderately better1211
Week 8 — A little better1814
Week 8 — About the same1222
Week 8 — A little worse13
Week 8 — Moderately worse13
Week 8 — Much worse02
Week 12 — Much better269
Week 12 — Moderately better1511
Week 12 — A little better1612
Week 12 — About the same722
Week 12 — A little worse23
Week 12 — Moderately worse02
Week 12 — Much worse01
Week 16 — Much better2612
Week 16 — Moderately better1312
Week 16 — A little better87
Week 16 — About the same1020
Week 16 — A little worse33
Week 16 — Moderately worse25
Week 16 — Much worse02
Week 20 — Much better2414
Week 20 — Moderately better156
Week 20 — A little better1013
Week 20 — About the same1020
Week 20 — A little worse34
Week 20 — Moderately worse24
Week 20 — Much worse00
Week 24 — Much better2714
Week 24 — Moderately better126
Week 24 — A little better138
Week 24 — About the same922
Week 24 — A little worse06
Week 24 — Moderately worse32
Week 24 — Much worse00
SecondarySerum Benralizumab Concentrations

Serum concentrations of benralizumab measured over time during the DB period to characterise the pharmacokinetics of benralizumab in participants with HES. Baseline is defined as the last valid value on or prior to the date of randomisation.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Geometric mean · ng/mL
Serum Benralizumab Concentrations
ng/mLBenra
Baseline3.699 ± 16.906
Week 4748.176 ± 238.842
Week 81384.403 ± 133.177
Week 161467.213 ± 184.478
Week 241764.068 ± 130.601
SecondaryAnti-Benralizumab Antibodies and Neutralizing Antibodies (nAbs)

Immunogenicity of benralizumab, as assessed by the incidence and prevalence of anti-drug antibodies (ADA), including nAbs, measured from baseline through the 24-week DB treatment period in participants with HES.

Time frame:
DB period (Baseline to Week 24)
Reported as:
Count of participants · Participants
Anti-Benralizumab Antibodies and Neutralizing Antibodies (nAbs)
ParticipantsBenraPlacebo
ADA negative (negative at all visits, baseline and post-baseline)5957
ADA positive at baseline and/or post-baseline (prevalence)89
ADA positive only at baseline00
ADA positive at both baseline and ≥ one post-baseline35
Treatment-emergent (TE) ADA positive/ADA incidence78
Non-treatment-emergent ADA positive11
Persistently positive ADA31
Transiently positive ADA23
TE-ADA positive with maximum post-baseline titre > median of maximum post-baseline titre43
nAb prevalence35
nAb incidence23

Adverse events

Collected over DB Treatment Period: From the first dose of investigational product (IP) through the end of the 24-week DB period. OLE Period: From the first dose of benralizumab in the OLE period (following completion of the DB period at Week 24) to the data cut-off date 07 May 2025. The duration of follow-up varied by participant, up to approximately 4.3 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra - DB1/67 (1.5%)5/67 (7.5%)23/67 (34.3%)
Placebo - DB0/66 (0%)5/66 (7.6%)18/66 (27.3%)
Benra - OLE0/65 (0%)11/65 (16.9%)42/65 (64.6%)
Placebo Switched to Benra - OLE0/61 (0%)10/61 (16.4%)45/61 (73.8%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventBenra - DBPlacebo - DBBenra - OLEPlacebo Switched to Benra - OLE
CholelithiasisHepatobiliary disorders0/670/660/651/61
Acquired haemophiliaBlood and lymphatic system disorders0/670/660/651/61
Hypereosinophilic syndromeBlood and lymphatic system disorders1/671/660/651/61
BradycardiaCardiac disorders0/670/660/651/61
IntussusceptionGastrointestinal disorders0/670/660/651/61
CellulitisInfections and infestations0/670/660/651/61
GastroenteritisInfections and infestations0/670/660/651/61
Infective exacerbation of asthmaInfections and infestations0/670/660/651/61
Pneumonia bacterialInfections and infestations0/671/660/651/61
Urinary tract infectionInfections and infestations0/670/660/651/61
Most frequent other events
Showing 10 of 28
Most frequent other events
EventBenra - DBPlacebo - DBBenra - OLEPlacebo Switched to Benra - OLE
Upper respiratory tract infectionInfections and infestations5/675/6615/6515/61
Covid-19Infections and infestations4/674/6611/6513/61
ArthralgiaMusculoskeletal and connective tissue disorders3/675/666/6511/61
HeadacheNervous system disorders11/675/665/659/61
NasopharyngitisInfections and infestations3/674/669/656/61
CoughRespiratory, thoracic and mediastinal disorders0/670/666/655/61
DiarrhoeaGastrointestinal disorders0/670/666/655/61
VomitingGastrointestinal disorders0/670/663/655/61
GastroenteritisInfections and infestations0/670/665/655/61
RhinitisInfections and infestations0/670/662/655/61

Baseline characteristics

Full Analysis Set: All participants who were randomized and received at least 1 dose of IP, irrespective of their protocol adherence and continued participation in the study.

Age, Continuous
Age, Continuous(years)BenraPlaceboTotal
Mean47.5 ± 18.6249.2 ± 18.8648.4 ± 18.68
Age, Customized
Age, Customized(Participants)BenraPlaceboTotal
>=12 - <18 years314
>=18 - <=21 years6612
>21 - <=50 years262349
>50 - <=65 years192241
>65 - <=75 years10919
>75 years358
Sex: Female, Male
Sex: Female, Male(Participants)BenraPlaceboTotal
Female433982
Male242751
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BenraPlaceboTotal
Hispanic or Latino112
Not Hispanic or Latino6665131
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BenraPlaceboTotal
White424587
Black or African American314
Asian101121
Other303
Not Reported9918
Region of Enrollment
Region of Enrollment(Participants)BenraPlaceboTotal
North America12921
Europe454590
Asia101121
Rest of World011
08

Study locations

52 sites
  • Research Site
    La Jolla, California 92037, United States
  • Research Site
    Atlanta, Georgia 30324, United States
  • Research Site
    Bethesda, Maryland 20892, United States
  • Research Site
    Ann Arbor, Michigan 48105, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Columbus, Ohio 43212, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Brussels, 1070, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Tianjin, 300020, China
  • Research Site
    Xiamen, 361015, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    København Ø, 2100, Denmark
  • Research Site
    Lille, 59037, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Strasbourg, 67091, France
  • Research Site
    Suresnes, 92151, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Kirchheim, 73230, Germany
  • Research Site
    Mannheim, 68167, Germany
  • Research Site
    Ahmedabad, 380013, India
  • Research Site
    Ajmer, 305001, India
  • Research Site
    Delhi, 110029, India
  • Research Site
    Haifa, 34362, Israel
  • Research Site
    Holon, 58100, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Kfar Saba, 44218, Israel
  • Research Site
    Petah Tikva, 49100, Israel
  • Research Site
    Ramat Gan, 5265601, Israel
  • Research Site
    Rehovot, 76100, Israel
  • Research Site
    Tel Aviv, 64239, Israel
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Chiba, 260-0852, Japan
  • Research Site
    Hamamatsu, 431-3192, Japan
  • Research Site
    Ichikawa-shi, 272-8516, Japan
  • Research Site
    Kawasaki-shi, 211-8510, Japan
  • Research Site
    Nishinomiya-shi, 663-8501, Japan
  • Research Site
    Osaka, 530-8480, Japan
  • Research Site
    Sendai, 980-8574, Japan
  • Research Site
    Rotterdam, 3015 GD, Netherlands
  • Research Site
    Chęciny, 26-060, Poland
  • Research Site
    Gdansk, 80-214, Poland
  • Research Site
    Lodz, 90-153, Poland
  • Research Site
    Seoul, 5505, South Korea
  • Research Site
    Santander, 39010, Spain
  • Research Site
    London, W2 1NY, United Kingdom
09

References and documents

Publications

  • Ogbogu PU, Roufosse F, Akuthota P, Kuna P, Groh M, Reiter A, Yokota A, Siddiqui SH, Mutsaers PGNJ, Li B, Khoury P, Bahadori LM, Bednarczyk A, Bouma G, Brooks LG, Ferreira J, Grindebacke H, Ho CN, Jain P, Palmer RL, Jison ML, Klion AD; NATRON study group. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. 2026 Jun;32(6):2017-2025. doi: 10.1038/s41591-026-04315-8. Epub 2026 Mar 31. PubMed 41917160 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in May 2025, 57 months.

Results were first posted in Jul 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2019
First posted
Dec 9, 2019
StartActual
Jul 20, 2020
Primary completionActual
May 7, 2025
CompletionEst.
Feb 28, 2027
Results first posted
Jul 10, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04191304
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 9, 2019
Start date
Jul 20, 2020
Primary completion
May 7, 2025
Completion
Feb 28, 2027 (estimated)
Results posted
Jul 10, 2026
Last update
Jul 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion